[161Tb]Tb-DOTA-N4MU01

N/A

Report date: 2025/11/06 13:43:25

Base Information

Drug Name[161Tb]Tb-DOTA-N4MU01

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Terbium > 161TbRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-NECTIN4

TargetsNectin-4

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversite Laval University Of Saskatchewan

China Registration ClassN/A

Develop Information

Active CompaniesUniversite Laval University Of Saskatchewan

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A